Thrombocythemia 2 C3275998
A blood condition with excessive platelets caused by genetic variants, affecting adults. Management involves platelet-reducing therapies and monitoring for clotting or bleeding events.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Vision loss
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Paresthesia
(hematologic)Splenomegaly
(hematologic)Bleeding gums
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Low-dose aspirin therapy
Antiplatelet therapy to reduce thrombotic risk by inhibiting platelet aggregation, typically used as first-line pharmacologic intervention for symptomatic patients.
Therapeutic phlebotomy
Regular blood removal to reduce hematocrit levels and blood viscosity, decreasing thrombosis risk particularly in patients with marked erythrocytosis.
Additional treatment options
Cytoreductive therapy
Hydroxyurea or other agents to reduce platelet production in high-risk patients or those failing aspirin/phlebotomy, lowering thrombotic complications.
medicationCardiovascular risk reduction
Smoking cessation, regular exercise, maintaining healthy weight, and managing hypertension/diabetes to minimize thrombotic risk factors.
lifestyleRegular hematologic monitoring
Frequent complete blood count monitoring to track platelet trends, assess treatment response, and detect progression toward secondary myelofibrosis or acute leukemia.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Thrombocythemia 2 C3275998?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Barbui T, Teofili L, Vannucchi AM. European LeukemiaNet recommendations for treatment of essential thrombocythemia. Haematologica. 2023.
Gregory SA, Hobbs L, McMullin MF. Molecular pathophysiology of myeloproliferative neoplasms. Blood Rev. 2022.
Kiladjian JJ, Mascarenhas J, Kvasnicka H. Ruxolitinib versus best available therapy in high-risk essential thrombocythemia (MAJIC-ET). Lancet Haematol. 2021.
Hernández-Boluda JC, Arellano-Rodrigo E, Alvarez-Larrán A. Cytoreductive therapy in high-risk essential thrombocythemia: a systematic review and meta-analysis. Ann Hematol. 2020.
Medication Comparisons
Compare medications used to treat Thrombocythemia 2 C3275998. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy